Claims

1. The use of a mussel adhesive protein ("MAP") as an active ingredient in the manufacture of a composition for the treatment of inflammation caused by an inflammatory skin disease caused by dermatitis, eczema, skin ulcer, herpes, psoriasis, erythema multiforme, chemo rash, skin cancer, folliculitis, hives or drug rash, polymorphous sunlight eruption or pathological hair loss or external otitis,

wherein the MAP comprises mytilus edulis foot protein 1 ("mefp-1"); and

wherein the composition is suitable for external skin application.

2. The use according to any one of claim 1, wherein the MAP concentration in the composition is 0.1 - 15.0 mg/ml.

3. The use according to any one of claim 1-2, wherein the MAP composition is a liquid formulation, a gel formulation, a lotion, a paste, a therapy patch, or a foam formulation.

4. The use according to any one of claims 1-3, wherein MAP in the composition is in a range of pH 1.0-7.0, and in particular, in a range of pH 3.0-6.5.

5. The use according to any one of claims 1- 4 wherein the composition is a medicine or a healthcare product.

6. The use according to any one of claims 1-5, wherein the composition is a foam formulation comprising MAP as the main active ingredient and a foaming agent matrix material, said foaming agent matrix material being one or any combination of hydroxypropyl methyl cellulose, gelatin, polyethylene glycol, sodium dodecyl sulfate, sodium fatty alcohol polyoxyethylene ether sulfonate, corn gluten powder and acrylamide.